Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Wenfeng Tianji Pharmaceuticals
Beijing, Chinatianjipharma.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Benvitimod (tapinarof) cream approved by NMPA in China on May 29, 2019, for mild-to-moderate plaque psoriasis under priority review; also marketed for atopic dermatitis and plaque psoriasis, with Phase 3 ongoing for moderate atopic dermatitis.[1][2][3][4][5]
- Therapeutic areas
- Dermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Dermavant SciencesJapan TobaccoTorii PharmaceuticalsCelestial PharmaceuticalsShenzhen Celestial PharmaWelichem BiotechGuangdong Zhonghao Pharmaceutical Co. Ltd.
Beyond the preview
Go deeper on Beijing Wenfeng Tianji Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Wenfeng Tianji Pharmaceuticals.